On Friday at 10:42 AM (Bangkok time), the share price of Medeze Group Public Company Limited (SET: MEDEZE) dropped by 3.39% or THB 0.30 to THB 8.55, with a trading value of THB 216.90 million.
Yuanta Securities projects that MEDEZE’s earnings for the third quarter of 2024 will increase by 12% quarter-on-quarter and 42% year-on-year. This growth is attributed to positive sentiment surrounding the Stem Cells and NK Cells segments, as well as improved profitability due to robust revenue growth.
The analyst anticipates an upward trajectory for MEDEZE’s performance in 3Q24, as full-year earnings for 2024 are expected to rise by 39% year-on-year, coupled with an average growth rate of 25% over the next two years, driven by both organic growth and business expansion. Additionally, MEDEZE plans to enhance profitability by implementing the Robotic Cell Culture System.
Yuanta Securities gives a ‘BUY’ recommendation for MEDEZE, setting a target price of THB 12.60 per share.
